Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Infect Dis J ; 37(11): 1107-1111, 2018 11.
Article in English | MEDLINE | ID: mdl-29742646

ABSTRACT

BACKGROUND: Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) are the leading causes of acute respiratory illness in children. Clinical burden of each infection on the respiratory distress in asthmatic patients remains unclear. The purpose of the study was to clarify the effect of these infections on the severity of asthmatic children in the seasonal outbreaks. METHODS: A total of 1,217 pediatric inpatients with hMPV (n = 114) or RSV (n = 1,103) infection in Yamaguchi prefecture, Japan, between 2011 and 2014 were enrolled. Bronchial asthma was defined as having more than 3 episodes of wheezing illness over 1 year of age. Infection was determined by the positive antigen test for each virus in the nasal specimens. RESULTS: The number of patients peaked at age 12-15 months in hMPV infection and at age 0-3 months in RSV infection. The proportion of hypoxic patients (40-50%) did not differ at any age between hMPV-infected and RSV-infected children. In the analysis of date from > 1 year old patients with hypoxia, hMPV-infection group was older (P = 0.036), and more frequently had history of asthma (P = 0.015) or abnormal chest roentgenogram (P < 0.001) than RSV-infection group. Multivariate analysis indicated that the hypoxia-associated factors were history of asthma in both hMPV (odds ratio [OR]: 15.8; P < 0.001) and RSV infections (OR, 2.2; P = 0.005), higher body temperature in hMPV infection (OR, 2.2; P = 0.009), and younger age in RSV infection (OR, 1.4; P = 0.004). CONCLUSIONS: Outbreaks of hMPV, rather than, RSV infection may have a greater impact on the development of hypoxic respiratory illness in asthmatic children.


Subject(s)
Asthma/virology , Paramyxoviridae Infections/epidemiology , Respiratory Syncytial Virus Infections/epidemiology , Adolescent , Asthma/complications , Child , Child, Preschool , Cost of Illness , Hospitalization , Humans , Hypoxia/epidemiology , Hypoxia/etiology , Infant , Infant, Newborn , Japan/epidemiology , Metapneumovirus/genetics , Metapneumovirus/isolation & purification , Paramyxoviridae Infections/complications , Respiratory Sounds/etiology , Respiratory Syncytial Virus Infections/complications , Respiratory Syncytial Virus, Human/genetics , Respiratory Syncytial Virus, Human/isolation & purification , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Seasons , Severity of Illness Index
2.
Microbiol Immunol ; 48(5): 377-87, 2004.
Article in English | MEDLINE | ID: mdl-15215625

ABSTRACT

Shiga toxins (Stxs, also referred to as verotoxins) were first described as a novel cytotoxic activity against Vero cells. In this study, we report the characterization of an Stx1-resistant (R-) stock of Vero cells. (1) When the susceptibility of R-Vero cells to Stx1 cytotoxicity was compared to that of Stx1-sensitive (S-) Vero cells by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, cell viability after 48-hr exposure to 10 pg/ml of Stx1 was greater than 80% and less than 15%, respectively. (2) Although both a binding assay of fluorescence-labeled Stx1 and lipid analysis indicated considerable expression of Gb3Cer, a functional receptor for Stxs, in both Vero cells, anti-Gb3Cer monoclonal antibodies capable of binding to S-Vero cells failed to effectively label R-Vero cells, suggesting a conformational difference in the Gb3Cer expressed on R-Vero cells. (3) The lipid analysis also showed that the R-Vero cells contained significant amounts of Gb4Cer. In addition, introduction of exogenous Gb4Cer into S-Vero cells slightly inhibited Stx1 cytotoxicity, suggesting some correlation between glycosphingolipid composition and Stx1 resistance. (4) Both butyrate treatment and serum depression eliminated the Stx1 resistance of R-Vero cells. (5) The results of the analysis by confocal microscopy suggest a difference in intracellular transport of Stx1 between R-Vero and S-Vero cells. Further study of R-Vero cells may provide a model of Stx1 resistance via distinct intracellular transport of Stx1.


Subject(s)
Cytotoxins/toxicity , Shiga Toxin 1/toxicity , Animals , Butyrates/pharmacology , Cell Survival , Chlorocebus aethiops , Cytotoxins/metabolism , Globosides/analysis , Microscopy, Confocal , Protein Transport , Shiga Toxin 1/metabolism , Trihexosylceramides/analysis , Trihexosylceramides/immunology , Vero Cells
3.
Mod Pathol ; 17(4): 423-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14976526

ABSTRACT

Surrogate light chains consisting of VpreB (CD179a) and lambda5 (CD179b) are expressed in precursor B cells lacking a complete form of immunoglobulin and are thought to act as substitutes for conventional light chains. Upon differentiation to immature and mature B cells, CD179a/b disappear and are replaced with conventional light chains. Thus, these molecules may be useful as essential markers of precursor B cells. To examine the expression of the surrogate light-chain components CD179a and CD179b in precursor B-cell lymphoblastic lymphoma, we analyzed tissue sections using immunohistochemistry techniques. Among a number of monoclonal antibodies for the surrogate light chains, VpreB8 and SL11 were found to detect CD179a and CD179b, respectively, in acetone-fixed fresh frozen sections. Moreover, we also observed VpreB8 staining in formalin-fixed, paraffin-embedded sections. Using these antibodies, we found that CD179a/b were specifically expressed in precursor B-cell lymphoblastic lymphomas, but not in mature B-cell lymphomas in childhood. Furthermore, other pediatric tumors that must be included in a differential diagnosis of precursor B-cell lymphoblastic lymphoma, including precursor T-cell lymphoblastic lymphoma, extramedullary myeloid tumors, and Ewing sarcoma, were also negative for both CD179a and CD179b. Our data indicate that CD179a and CD179b may be important markers for the immunophenotypic diagnosis of precursor B-cell lymphoblastic lymphomas.


Subject(s)
B-Lymphocytes/metabolism , Biomarkers, Tumor/metabolism , Lymphoma, B-Cell/metabolism , Membrane Glycoproteins/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Adolescent , B-Lymphocytes/pathology , Cell Line, Tumor , Child , Child, Preschool , Flow Cytometry , Humans , Immunoenzyme Techniques , Immunoglobulin Light Chains , Immunoglobulin Light Chains, Surrogate , Infant , Lymphoma, B-Cell/diagnosis , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Sensitivity and Specificity
4.
J Immunol ; 170(1): 252-60, 2003 Jan 01.
Article in English | MEDLINE | ID: mdl-12496407

ABSTRACT

We previously reported that the cross-linking of cluster of differentiation (CD)24 induces apoptosis in Burkitt's lymphoma cells and that this phenomenon can be enhanced by a B cell Ag receptor (BCR)-mediated signal. In this study, we extend our previous observation and report that CD24 also mediated apoptosis in human precursor-B acute lymphoblastic leukemia cell lines in the pro-B and pre-B stages accompanying activation of multiple caspases. Interestingly, simultaneous cross-linking of pre-BCR clearly inhibited CD24-mediated apoptosis in pre-B cells. We also observed that mitogen-activated protein kinases (MAPKs) were involved in the regulation of this apoptotic process. Pre-BCR cross-linking induced prompt and strong activation of extracellular signal-regulated kinase 1, whereas CD24 cross-linking induced the sustained activation of p38 MAPK, following weak extracellular signal-regulated kinase 1 activation. SC68376, a specific inhibitor of p38 MAPK, inhibited apoptosis induction by CD24 cross-linking, whereas anisomycin, an activator of p38 MAPK, enhanced the apoptosis. In addition, PD98059, a specific inhibitor of MEK-1, enhanced apoptosis induction by CD24 cross-linking and reduced the antiapoptotic effects of pre-BCR cross-linking. Collectively, whether pre-B cells survive or die may be determined by the magnitude of MAPK activation, which is regulated by cell surface molecules. Our findings should be important to understanding the role of CD24-mediated cell signaling in early B cell development.


Subject(s)
Antigens, CD/physiology , Apoptosis/immunology , B-Lymphocyte Subsets/pathology , Down-Regulation/immunology , Membrane Glycoproteins/physiology , Neoplastic Stem Cells/pathology , Signal Transduction/immunology , Antibodies, Monoclonal/metabolism , Antigens, CD/immunology , Antigens, CD/metabolism , B-Lymphocyte Subsets/enzymology , B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/metabolism , Burkitt Lymphoma/enzymology , Burkitt Lymphoma/immunology , CD24 Antigen , Caspases/metabolism , Enzyme Activation/immunology , Humans , Membrane Glycoproteins/immunology , Membrane Glycoproteins/metabolism , Mitogen-Activated Protein Kinases/metabolism , Neoplastic Stem Cells/enzymology , Neoplastic Stem Cells/immunology , Neoplastic Stem Cells/metabolism , Pre-B Cell Receptors , Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Receptors, Antigen, B-Cell , Tumor Cells, Cultured
5.
Exp Hematol ; 30(10): 1115-23, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12384141

ABSTRACT

OBJECTIVE: Recent reports have indicated that monocytes express receptors for the granulocyte colony-stimulating factor (G-CSF). The direct effects of G-CSF on cytokine secretion in monocytes were examined. MATERIALS AND METHODS: A monocytic cell line NOMO-1 that secretes multiple cytokines upon stimulation with lipopolysaccharide (LPS) was used. Normal human monocytes were purified by negative selection using magnetic beads. Cells pretreated with or without G-CSF were stimulated with LPS, and the subsequent concentrations of cytokines and chemokines in supernatants were determined by sandwich enzyme-linked immunosorbent assay. RESULTS: NOMO-1 cells were found to express receptors for G-CSF. Although G-CSF stimulation did not induce cytokine secretion, pretreatment with G-CSF significantly attenuated LPS-stimulated secretion of the proinflammatory cytokines tumor necrosis factor-alpha and interleukin (IL)-12 in NOMO-1 cells. Simultaneously, however, G-CSF pretreatment apparently enhanced LPS-induced secretion of IL-10 and monocyte chemoattractant protein-1, whereas secretions of IL-1beta, IL-6, and IL-8 were unaffected. When normal human monocytes from healthy volunteers were similarly examined, marked individual variations in LPS-induced secretion of cytokines were observed. Although some exceptions exist, a similar tendency as to the effects of G-CSF treatment on cytokine secretions as that in NOMO-1 cells was observed in human monocytes. CONCLUSIONS: Our data suggest that G-CSF directly affects monocytes and modulates their cytokine secretion. NOMO-1 cells can provide an alternate model for in vitro culture of monocytes to investigate the effects of G-CSF on cytokine secretion by these cells.


Subject(s)
Cytokines/metabolism , Granulocyte Colony-Stimulating Factor/pharmacology , Monocytes/physiology , Cell Line , Chemokines/metabolism , DNA Primers , Humans , Kinetics , Lipopolysaccharide Receptors/drug effects , Lipopolysaccharide Receptors/genetics , Lipopolysaccharides/pharmacology , Monocytes/drug effects , RNA, Messenger/genetics , Receptors, Granulocyte Colony-Stimulating Factor/drug effects , Receptors, Granulocyte Colony-Stimulating Factor/genetics , Recombinant Proteins , Reverse Transcriptase Polymerase Chain Reaction
6.
J Infect Dis ; 185(6): 785-96, 2002 Mar 15.
Article in English | MEDLINE | ID: mdl-11920296

ABSTRACT

Nitrobenzylthioinosine (NBTI), a nucleoside-transport inhibitor, has been found to possess the ability to prevent the cytotoxic action of Shiga toxin (Stx) 1 in human renal cortical epithelial cells (HRCECs), thereby protecting HRCECs from cell death. Further examination revealed that NBTI does not affect either the binding or the endocytosis of Stx1 but alters the intracellular transport of Stx1. Generally, endocytosed Stx1 is thought to be transported from endosomes to the endoplasmic reticulum. In NBTI-treated cells, however, the endocytosed Stx1 is delivered to an early endosome, but no further transportation occurs. Moreover, Stx1 is rapidly excreted from NBTI-treated HRCECs, preventing the accumulation of Stx1. Investigation of the NBTI-mediated protection mechanism against Stx cytotoxicity may provide insights into the analysis of Stx-mediated cell damage and lead to improvements in therapeutic approaches for diseases caused by Stx.


Subject(s)
Kidney Cortex/drug effects , Shiga Toxin 1/toxicity , Thioinosine/analogs & derivatives , Thioinosine/pharmacology , Adenosine Triphosphate/analysis , Biological Transport/drug effects , Cells, Cultured , Deoxyglucose/pharmacology , Epithelial Cells/drug effects , Golgi Apparatus/metabolism , Humans , Shiga Toxin 1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...